These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10586007)

  • 1. Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients.
    Fox-Wheeler S; Heller L; Salata CM; Kaufman F; Loro ML; Gilsanz V; Haight M; Umman GC; Barton N; Church JA
    Pediatrics; 1999 Dec; 104(6):e73. PubMed ID: 10586007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial.
    Strawford A; Barbieri T; Van Loan M; Parks E; Catlin D; Barton N; Neese R; Christiansen M; King J; Hellerstein MK
    JAMA; 1999 Apr; 281(14):1282-90. PubMed ID: 10208143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone.
    Earthman CP; Reid PM; Harper IT; Ravussin E; Howell WH
    JPEN J Parenter Enteral Nutr; 2002; 26(6):357-65. PubMed ID: 12405647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy.
    Porro LJ; Herndon DN; Rodriguez NA; Jennings K; Klein GL; Mlcak RP; Meyer WJ; Lee JO; Suman OE; Finnerty CC
    J Am Coll Surg; 2012 Apr; 214(4):489-502; discussion 502-4. PubMed ID: 22463890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial.
    Burch PT; Spigarelli MG; Lambert LM; Loftus PD; Sherwin CM; Linakis MW; Sheng X; LuAnn Minich L; Williams RV
    Congenit Heart Dis; 2016 Dec; 11(6):693-699. PubMed ID: 27257953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety.
    Orr R; Fiatarone Singh M
    Drugs; 2004; 64(7):725-50. PubMed ID: 15025546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of oxandrolone and exercise on muscle mass and function in children with severe burns.
    Przkora R; Herndon DN; Suman OE
    Pediatrics; 2007 Jan; 119(1):e109-16. PubMed ID: 17130281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anabolic steroid now available.
    AIDS Patient Care STDS; 1996 Apr; 10(2):134. PubMed ID: 11361700
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment.
    Przkora R; Jeschke MG; Barrow RE; Suman OE; Meyer WJ; Finnerty CC; Sanford AP; Lee J; Chinkes DL; Mlcak RP; Herndon DN
    Ann Surg; 2005 Sep; 242(3):384-9, discussion 390-1. PubMed ID: 16135924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trials for wasting drug.
    Posit Aware; 1996; 7(6):5-6. PubMed ID: 11363980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn.
    Jeschke MG; Finnerty CC; Suman OE; Kulp G; Mlcak RP; Herndon DN
    Ann Surg; 2007 Sep; 246(3):351-60; discussion 360-2. PubMed ID: 17717439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with an anabolic agent is associated with improvement in respiratory function in persons with tetraplegia: a pilot study.
    Spungen AM; Grimm DR; Strakhan M; Pizzolato PM; Bauman WA
    Mt Sinai J Med; 1999 May; 66(3):201-5. PubMed ID: 10377553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anabolic effects of oxandrolone after severe burn.
    Hart DW; Wolf SE; Ramzy PI; Chinkes DL; Beauford RB; Ferrando AA; Wolfe RR; Herndon DN
    Ann Surg; 2001 Apr; 233(4):556-64. PubMed ID: 11303139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-associated wasting: brief review and discussion of the impact of oxandrolone.
    Taiwo BO
    AIDS Patient Care STDS; 2000 Aug; 14(8):421-5. PubMed ID: 10977971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid.
    Demling RH; DeSanti L
    Burns; 2003 Dec; 29(8):793-7. PubMed ID: 14636753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of testosterone in the AIDS wasting syndrome.
    Corcoran C; Grinspoon S
    AIDS Clin Care; 1999 Apr; 11(4):25-6, 33-4. PubMed ID: 11366208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anabolic steroid oxandrolone increases muscle mass in prepubertal boys with constitutional delay of growth.
    Papadimitriou A; Preece MA; Rolland-Cachera MF; Stanhope R
    J Pediatr Endocrinol Metab; 2001 Jun; 14(6):725-7. PubMed ID: 11453521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia.
    Langer CJ; Hoffman JP; Ottery FD
    Nutrition; 2001 Jan; 17(1 Suppl):S1-20. PubMed ID: 11428126
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxandrolone, used for treatment of wasting disease in HIV-1-infected patients, does not diminish the antiviral activity of deoxynucleoside analogues in lymphocyte and macrophage cell cultures.
    Segal DM; Perez M; Shapshak P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):215-9. PubMed ID: 10077168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant anabolic agents: a case report on the successful use of oxandrolone in an HIV-positive patient with chronic stasis ulceration.
    Cioroiu M; Hanan SH
    J Wound Ostomy Continence Nurs; 2001 Jul; 28(4):215-8. PubMed ID: 11452258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.